V122I TTR Cardiac Amyloidosis in Patients of African Descent: Recognizing a Missed Disease or the Dog That Didn't Bark?

@article{Alexander2016V122ITC,
  title={V122I TTR Cardiac Amyloidosis in Patients of African Descent: Recognizing a Missed Disease or the Dog That Didn't Bark?},
  author={Kevin M. Alexander and Rodney H Falk},
  journal={Circulation. Heart failure},
  year={2016},
  volume={9 9}
}
> Gregory: “Is there any other point to which you would wish to draw my attention?” > > Holmes: “To the curious incident of the dog in the night-time.” > > Gregory: “The dog did nothing in the night-time.” > > Holmes: “That was the curious incident.” > > —Arthur Conan Doyle, “Silver Blaze” in The Memoirs of Sherlock Holmes Cardiac amyloidosis is caused by the aggregation and deposition of misfolded proteins in the extracellular space of the myocardium. The heart is one of multiple… 
Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology
TLDR
The data support the fact that Hereditary Transthyretin-Related Amyloidosis is underdiagnosed in polyneuropathy and cardiomyopathy patients and routine implementation of genetic testing is recommended in patients with unexplained polyneurpathy and/or cardiopathy to accelerate the earlier diagnosis and the time-sensitive treatment initiation.
Cardiac amyloidosis: a review of the literature and a practical approach for the clinicians
TLDR
The most updated and recent treatment strategies to cure amyloidosis are highlighted and the typing of precursor proteins is mandatory since therapy differs accordingly and thus guiding therapy.
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
TLDR
It is found that molecular interactions reflected in better binding enthalpy may be critical for development of TTR stabilizers with improved potency and selectivity and hypothesize that optimizing the bindingEnthalpy could have implications for designing therapeutic agents for other amyloid diseases.

References

SHOWING 1-10 OF 13 REFERENCES
Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome
TLDR
Factors at baseline associated with a worse outcome in ATTRwt are positive troponin T, a pacemaker, and NYHA class IV symptoms, and the age of the patient at diagnosis and NT pro‐BNP level can aid in distinguishing AT TRwt from AL amyloidosis.
Evolving landscape in the management of transthyretin amyloidosis
TLDR
The TTR stabilizers tafamidis and diflunisal slow disease progression in some patients with ATTR amyloidosis with polyneuropathy, and the postulated synergistic effect of doxycycline and tauroursodeoxycholic acid on dissolution of amyloids is under investigation.
Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2‐macroglobulin and tau: A population‐based autopsy study
TLDR
This population‐based study shows that SSA is very common in old individuals, affecting one‐quarter of people aged over 85 years, and myocardial infarctions and variation in the genes for α2M and tau may be associated with SSA.
Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis.
TLDR
In Afro-Caribbean patients, ATTR V122I is an underappreciated cause of heart failure, and cardiomyopathy is often misattributed to hypertension.
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
TLDR
ATTRwt is an underdiagnosed disease that accounts for a significant number (13%) of HFpEF cases and the effect of emerging TTR-modifying drugs should be evaluated in these patients.
The amyloidogenic V122I transthyretin variant in elderly black Americans.
TLDR
Genotype status for the transthyretin gene (TTR) was determined in 3856 black participants in the Atherosclerosis Risk in Communities study and a significant difference in mortality was not detected, a finding that contrasts with prior observations; however, the risk of heart failure was increased among carriers.
Transthyretin V122I in African Americans with congestive heart failure.
...
1
2
...